Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-ESBL IgY is an oral biologic therapy composed of polyclonal chicken egg yolk-derived immunoglobulin Y (IgY) antibodies. It is specifically engineered to target and neutralize extended-spectrum beta-lactamase (ESBL)-producing bacteria, primarily *Klebsiella pneumoniae* and *Escherichia coli*, within the gastrointestinal tract. Developed by researchers at Uppsala University, the drug is intended to eradicate intestinal carriage of these antibiotic-resistant pathogens, thereby reducing the risk of endogenous infection and horizontal transmission. Although it reached Phase II clinical testing, the trial was terminated early due to challenges in patient recruitment and high mortality in the target population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anti-ESBL IgY.